Abstract:Background B-cell maturation antigen (BCMA) is a potential therapeutic target in treatment of patients with MM. BCMA is widely expressed at the surface of myeloma cells and induces proliferative signals. BCMA-directed BCMA antibody conjugated with toxin has recently demonstrated outstanding anti-tumor responses and acceptable tolerability in MM treatment, allowing patients to achieve deeper responses with minimally added toxicity. Methods We used ELISA and FACS to verify AP163 can be combined with CD3/BCMA protein on the cell surface. We used the reporter gene method to verify that it induced T cell activation and target cell killing. In vivo, efficacy was studied in NCI-H929 and Raji xenograft models in female NPG mice. NPG mice were injected subcutaneously into the right dorsal flank with NCI-H929/Raji cells and human PBMC. Then the mice were treated with AP163 and tumor volume was measured twice/week. Cynomolgus monkeys were mainly used for toxicity testing. Intravenous administration is consistent with clinical administration. Its main toxicological target is the increase of cytokines and a series of adverse reactions. Results we constructed AP163 which binds to BCMA-expressing cell lines. AP163 induced both types of cell crosslinking, followed by T cell activation, cytokine production, proliferation and redirected target cell killing, with EC50 values in the picomolar range. The affinities of AP163 with human and cynomolgus CD3 are comparable. In vitro, AP163 only induced minimal cytokine release in the presence of BCMA target. When administered to mice bearing human MM xenografts and human T cells, AP163 eradicated subcutaneous tumors in two xenograft models tested and significantly delayed tumor growth at doses as low as 0.04mg/kg. AP163 displayed a 9-h half-life in cynomolgus and was well tolerated in non-human primates, even at high doses up to 5 mg/kg. Conclusions AP163 clears tumor cells in a BCMA+ and T-cell dependent manner in vitro and in vivo. Our preclinical data suggest that AP163 induces less cytokine secretion than a conventional bispecific in vitro, with reduction of tumor cell in vivo. AP163 is highly efficacious, safe and convenient for the treatment of patients with MM. Legal entity responsible for the study National Engineering Laboratory of High Level Expression In Mammalian Cells. Funding Has not received any funding. Disclosure All authors have declared no conflicts of interest.

Preliminary study of inhibiting MM CSCs by ABCG2 monoclonal antibody in combination with NPs-PTX in vitro

Anti-ABCG2 monoclonal antibody in combination with paclitaxel nanoparticles against cancer stem-like cell activity in multiple myeloma.

Gamma-Fe2O3 nanoparticles increase therapeutic efficacy of combination with paclitaxel and anti-ABCG2 monoclonal antibody on multiple myeloma cancer stem cells in mouse model.

Targeted therapeutic effect of anti-ABCG2 antibody combined with nano silver and vincristine on mouse myeloma cancer stem cells

Target therapy of multiple myeloma by PTX-NPs and ABCG2 antibody in a mouse xenograft model

Enhancing the Anti-Multiple Myeloma Efficiency in a Cancer Stem Cell Xenograft Model by Conjugating the ABCG2 Antibody with Microbubbles for a Targeted Delivery of Ultrasound Mediated Epirubicin.

Fe 3 O 4 Nanoparticle Loaded Paclitaxel Induce Multiple Myeloma Apoptosis by Cell Cycle Arrest and Increase Cleavage of Caspases in Vitro

Fe3O4 nanoparticle loaded paclitaxel induce multiple myeloma apoptosis by cell cycle arrest and increase cleavage of caspases in vitro

Inhibitory Effect of Epirubicin-Loaded Lipid Microbubbles with Conjugated Anti-Abcg2 Antibody Combined with Therapeutic Ultrasound on Multiple Myeloma Cancer Stem Cells

Pretreatment of Umbilical Cord Derived MSCs with IFN-γ and TNF-α Enhances the Tumor-Suppressive Effect on Acute Myeloid Leukemia.

N-Propionyl Polysialic Acid Precursor Enhances the Susceptibility of Multiple Myeloma to Antitumor Effect of Anti-Nprpsa Monoclonal Antibody.

Experimental Study on the Drug Resistance Gene ABCG2:a Marker of Small Population Cells

Paclitaxel-Fe3O4 nanoparticles inhibit growth of CD138(-) CD34(-) tumor stem-like cells in multiple myeloma-bearing mice.

Effect of magnetic nanoparticles of Fe3O4 and 5-bromotetrandrine on reversal of multidrug resistance in K562/A02 leukemic cells.

Experimental Study on the Therapeutic Effect of Combined Antihuman IgG Antibody with Mitomycin C on Human Bladder Cancer Cells

The inhibitory effect of paclitaxel-loaded lipid microbubbles combined with ultrasound on multiple myeloma cells in vitro

Conditioned Medium of Mesenchymal Stromal Cells Inhibits Cell Proliferation and Promotes Sensitivity of Paclitaxel in MDA-MB-231 Cells

Dual depletion of myeloid-derived suppressor cells and tumor cells with self-assembled gemcitabine-celecoxib nano-twin drug for cancer chemoimmunotherapy

Sequential depletion of myeloid-derived suppressor cells and tumor cells with a dual-pH-sensitive conjugated micelle system for cancer chemoimmunotherapy

A Novel Bispecific BCMAxCD3 T Cell-Engaging Antibody That Treat Multiple Myeloma (MM) with Minimal Cytokine Secretion

Effective therapy of advanced breast cancer through synergistic anticancer by paclitaxel and P-glycoprotein inhibitor